Latest Regulatory News

Caravel Minerals reports substantial progress on its Definitive Feasibility Study for the Caravel Copper Project, advancing engineering, environmental approvals, and strategic partnerships toward development.

The Supreme Court of New South Wales has approved Southern Cross Media's acquisition of Seven West Media, setting the stage for a significant media industry consolidation early next year.

Janus Henderson Investors has announced the distribution timetable for its Global Sustainable Equity Active ETF for the period ending December 2025, outlining key dates and reinvestment options for investors.

Scorpion Minerals has executed a binding option agreement to acquire the Old Prospect tenements within its Pharos Gold Project, adding a JORC-compliant resource of over 21,600 ounces of gold. The acquisition consolidates tenure along a highly prospective 5km structural corridor in Western Australia’s Murchison region.

Chimeric Therapeutics has raised $8.4 million to fully fund its lead CHM CDH17 CAR-T Phase 1/2 trial through Phase 1, while initiating a strategic reset to sharpen focus and reduce costs.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Neurizon Therapeutics has locked in a $44 million funding package to fully support its lead drug NUZ-001 in the HEALEY ALS Platform Trial, marking a critical step toward potential regulatory approval and broader neurodegenerative applications.

OZZ Resources has entered a binding option agreement with Scorpion Minerals, offering an exclusive chance to acquire its key tenements for $2.6 million plus a gold production royalty. The deal awaits shareholder approval and hinges on several regulatory and operational conditions.

BCI Minerals has secured crucial environmental approvals to proceed with its optimized dredging strategy at the Mardie Salt Operation, setting the stage for first salt shipments by late 2026.

Invion Limited’s partner Hanlim Pharm, backed by South Korea’s government grant, has secured up to A$2 million in non-dilutive funding to advance preclinical studies of HL270 for oesophageal cancer, paving the way for human trials in Australia.

Rox Resources has completed a $200 million capital raise, including a $134 million second tranche placement, to fund development of its Youanmi Gold Project in Western Australia.

Minbos Resources has obtained a crucial ASX waiver allowing it to issue shares under its Share Purchase Plan without the usual shareholder approval, aligning pricing with its recent Placement and aiming to maintain fairness among investors.